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Abstract
Background: Numerous frailty screening instruments are available, but their applicability for identifying frailty in patientswith
end-stage renal disease (ESRD) is unknown. We aimed to investigate the diagnostic accuracy of three instruments used for
frailty screening in an ESRD population.
Methods: The study was conducted in 2013 in a teaching hospital in The Netherlands and included patients receiving
haemodialysis, peritoneal dialysis and pre-dialysis care. We determined the sensitivity and speciﬁcity of three screening
instruments: the Groningen Frailty Indicator (GFI), the Identiﬁcation of Seniors at Risk–Hospitalized Patients (ISAR-HP) and the
Veiligheidsmanagementsysteem (VMS), which is a safetymanagement system for vulnerable elderly patients. The Frailty Index
was the gold standard used.
Results: The prevalence of frailty was 37% in a total of 95 participants with ESRD [mean age 65.2 years (SD 12.0), 57% male].
Frailty prevalence in participants ≥65 years of age and <65 years of age was 44% and 28%, respectively (P = 0.11). Sensitivity and
speciﬁcity for frailty of the GFI were 89% and 57%, respectively; ISAR-HP 83% and 77%, respectively; and VMS 77% and 67%,
respectively.
Conclusions: Although the GFI showed the highest sensitivity, it is not yet possible to propose a ﬁrm choice for one of these
screening instruments or speciﬁc items due to the small scale of the study. Since there is a high prevalence of frailty in ESRD
patients, translation and testing of the effectiveness of screening using the GFI in the prognostication and prevention of
development or deterioration of frailty in this population should be the next step.
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Introduction
With a growing ageing population and improved medical care,
there is an increasing number of elderly patients with chronic
kidney disease (CKD) [1, 2], many of whom progress to end-
stage renal disease (ESRD) and become dialysis dependent
[1, 2]. More than 5000 patients in The Netherlands and >500 000
patients in the United States undergo dialysis treatment, of
whom more than half are ≥65 years of age [2]. The prognosis of
older patients with ESRD after starting dialysis is poor; after dia-
lysis initiation, mortality is >35% in patients >70 years, and the
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mortality rate increases to 50% in patients >80 years [3]. Addition-
ally, older patients are at high risk of impaired functional status
and comorbidity [3]. However, prognosis varies substantially
among older patients. Therefore, it is important to identify
those who are at high risk of mortality and functional decline
and those who will beneﬁt from dialysis treatment.
The concept of frailty—a state of low homeostatic reserve
leading to high vulnerability for sudden adverse health changes
—has recently emerged as a potential predictor of prognosis in
the ESRD population [4]. The prevalence of frailty is high in the
ESRD population. In addition, frail patients undergoing haemodi-
alysis had 2.6 times higher risk of mortality [95% conﬁdence
interval (CI) 1.04–6.49] and 1.4 times higher risk of hospitalization
(95%CI 1.00–2.03) comparedwith non-frail patients, independent
of age, gender, comorbidity and disability [4].
A comprehensive geriatric assessment (CGA) is the gold
standard to deﬁne frailty in patients, but consensus on the
exact operational deﬁnition of frailty is still lacking. In research
settings, frailty is mostly operationalized by the Fried phenotype
or the Frailty Index (FI) [5, 6]. Performing aCGA is time-consuming
and requires clinical expertise from the investigator and endur-
ance from the patient. Therefore, several screening instruments
for frailty have been developed, such as the the Groningen Frailty
Indicator (GFI), the Identiﬁcation of Seniors at Risk–Hospitalized
Patients (ISAR-HP) and the Veiligheidsmanagementsysteem
(VMS;Dutch safetymanagement system) [7–9]. These instruments
aim to select frail patients who would beneﬁt most from CGA by
assessing their risk for frailty. Theyhave beenprimarily developed
for use in clinical settings and general populations, but they are
also used in research settings and speciﬁc patient populations.
However, none of these instruments have been speciﬁcally devel-
oped for or validated for use in an ESRD population [10, 11].
Despite the high prevalence of frailty and the associated risk
of adverse outcomes, it would be cost effective to identify those
patients at high risk of adverse outcomes, particularly in the
presence of time and resources limitations. Therefore, the aim
of this study was to determine the diagnostic value, speciﬁcally
the sensitivity, of three screening instruments for identifying
frailty in an ESRD population.
Materials and methods
Study population
This prospective study was conducted at a single dialysis centre
in a secondary teaching hospital in The Netherlands between
September 2013 and December 2013. Patients >18 years of age re-
ceiving chronic haemodialysis, chronic peritoneal dialysis, or
pre-dialysis care were included in the study. The pre-dialysis
care group consisted of (i) patients with an estimated glomerular
ﬁltration rate (eGFR) <20 mL/min/1.73 m2 but who did not yet
need renal replacement therapy and (ii) patients who were ex-
pected to be dependent on renal replacement therapy within a
considerable time frame due to a recent decline in kidney func-
tion. The study was approved by the Medical Ethics Committee
(METC) of the Academic Medical Center Amsterdam (reference
number W13_164 # 13.17.0209). Written informed consent was
obtained from all participants.
Data collection
At enrolment, trained research staff collected information from
medical charts, including comorbidities as measured by the
Charlson comorbidity index [12]. The eGFR was calculated
using the four-variable Modiﬁcation of Diet in Renal Disease
(MDRD) formula [13]. Participants were asked to complete a ques-
tionnaire and they performed a set of function tests supervised
by trained research staff (Supplementary data, Table S1).
Maximal grip strength (average of three measurements) was
measured in the dominant hand using a type 5030J1 Jamar hy-
draulic dynamometer. Walking speed (normal and rapid pace)
was measured as the fastest time of two measurements [14].
Non-recordable grip strength or inability to walk were scored as
positive items for all frailty screening instruments.
Frailty assessment
Frailty status was established by a medical student according to
the FI [6, 14].Weused 38 variables, consisting of physical, psycho-
logical, social and cognitive items but excluding shoulder
strength and peak ﬂow measurement, and used cut-off points
as suggested by Searle et al. [14] (Supplementary data, Table S1).
The FI represented the total score of positive items as a propor-
tion of all items measured. An FI score <0.25 was considered as
non-frail and an FI score of ≥0.25 as frail [14].
The discriminative value was assessed for three different
frailty screening instruments by comparing with the FI as the
gold standard. The GFI consists of 15 items of self-reported
limitations grouped in four domains: physical, cognitive, psycho-
logical and social. A score of≥4 is considered as frail (Supplemen-
tary data, Table S2) [7]. The VMS for the vulnerable elderly is a
Dutch risk assessment tool to identify elderly patients at risk of
functional decline both during and after hospital admission [8].
Based on expert opinion, the VMS for the vulnerable elderly con-
sists of 13 risk-related items grouped in four domains: delirium,
falls, malnutrition and functional impairment. A positive score
in one or more domain(s) is considered as high risk for frailty
(Supplementary data, Table S2). The ISAR-HP [9] is based on the
ISAR for the Emergency Department. It is a simple four-item
risk assessment instrument for functional decline both during
and after hospital admission that was developed and validated
in adults ≥aged 65 years of age [9, 15, 16]. A score of ≥2 was con-
sidered as high risk for frailty (Supplementary data, Table S2).
The VMS and ISAR-HP were originally developed for screening
the risk for functional decline; they assess domains that are
associated with the incidence of frailty and highly correlate
with functional decline [17]. In our study, we used both screening
instruments for assessing frailty because they are commonly
used for this purpose in clinical practice.
Statistical analysis
Descriptive statistics were given for all baseline demographic
and clinical data. Baseline characteristics were compared be-
tween frail and non-frail patients. Normally and non-normally
distributed continuous variables and nominal variables were
tested using the Student’s t-test, Mann–Whitney U-test or chi-
square test. Data from participants were excluded from the ana-
lysis of an instrument if they hadmissing values for >20% per in-
strument [11]. Sensitivity, speciﬁcity and positive and negative
predictive values of the three frailty screening instruments
were calculated, with the FI as the gold standard. The statistical
signiﬁcance level was set at 0.05. All analyses were performed
using Statistical Package for Social Sciences (SPSS) software,
version 20.



























Of a total of 144 patients, 95 (66%) participated in this study. Indi-
viduals in the included and non-responders groups were similar
with respect to age, treatment modality and Charlson comorbid-
ity index. In the included group, there was a lower proportion of
females compared with the non-responders group (43% versus
68%, respectively; P = 0.004). The mean age of the 95 participants
was 65.2 years (SD 12.0; range 27–88 years). Forty-two participants
(44%) were undergoing haemodialysis and 14 (15%) peritoneal
dialysis and 39 (41%) were receiving pre-dialysis care.
Frailty
Of the total study population, 37% were considered frail accord-
ing to the FI (44% of participants >65 years of age and 28% in
the younger group) (P = 0.11). As shown in Table1, of the frail peo-
ple more patients were female (60%) than of the non frail (33%) (P
= 0.01). No difference was found in age between frail [mean 66.6
years (SD 13.5); P = 0.39] and non-frail individuals [mean 64.4
years (SD 11.1)]. Correction for gender or treatment modality
did not alter this result. Frail participants had a (1 point) higher
Charlson comorbidity index score {median 4 [interquartile
range (IQR) 3–6]} compared with non-frail participants [median
3 (IQR 2–5); P = 0.02]. Treatment modality did not differ between
frail andnon-frail participants. Table 2 shows therewasno differ-
ence observed in the prevalence of frailty between dialysis and
pre-dialysis patients.
Screening instruments
Table 3 shows the sensitivity and speciﬁcity of the three screen-
ing instruments, with the FI as the gold standard. Of the three
instruments, the GFI had the highest sensitivity (89%) and the
lowest speciﬁcity (57%). In addition, the GFI had the highest pro-
portion of participants screened as frail (i.e. 57 participants), with
the lowest positive predictive value of 54.4%, whereas it also
showed the highest negative predictive value of 89.5%. The
ISAR-HP had the highest positive predictive value of 67.4% in
this population compared with the other two instruments.
Discussion
This study showed that different short questionnaire–based
screening instruments, i.e. the GFI, ISAR-HP and VMS, can all be
applied to the ESRD population to screen for frailty in both young
and older ESRD patients. Of these three screening instruments,
the GFI showed the highest sensitivity and negative predictive
value for screening frailty in dialysis and pre-dialysis patients,
with the FI as the gold standard. In addition, the ISAR-HP also
showed comparable performance to that of the GFI, with slightly
lower negative predictive value, and had the highest positive pre-
dictive value of all three instruments.
In this study, which included adults undergoing haemodialy-
sis, peritoneal dialysis or pre-dialysis care, the prevalence of
frailty exceeded one-third. The prevalence of frailty was high in
young, as well as older, ESRD patients, and no association be-
tween age and frailty was found in this population. These ﬁnd-
ings suggest that screening for frailty should be performed not
only in ESRD patients ≥65 years of age, but also in all younger
ESRD patients, given that more than a quarter of patients <65
years of age in this study were identiﬁed as frail.
The GFI is an effective tool for the identiﬁcation of those who
are at high risk for frailty and who may beneﬁt from a CGA. The
test is easy to administer, and our study showed that it has
strengths as a screening tool for frailty in an ESRD population, in-
cluding high sensitivity. A limitation for its use is that the
Table 1. Patient characteristics: frailty status, according to the Frailty Index
Characteristic Non-frail (n = 60) Frail (n = 35) P-value
Female, % 20 (33.3) 21 (60.0) 0.01
Age, years 64.4 (± 11.1) 66.6 (± 13.5) 0.39
Race, Caucasian, % 58 (96.7) 33 (94.3) 0.42
Treatment modality, %
HD 25 (41.7) 17 (48.6) 0.80
PD 9 (14.5) 5 (15.2)
Pre-dialysis 26 (43.3) 13 (37.1)
Body mass index 27.1 (24.0–29.8) 27.0 (25.0–29.4) 0.81
Laboratory
eGFR, mL/min/1.73 m2 (non-dialysis, n = 39) 14.0 (13.0–16.0) 16.0 (13.5–20.5) 0.10
Albumin, g/dL 3.49 (± 0.36) 3.33 (± 0.53) 0.10
Haemoglobin, g/dL 11.47 (± 1.21) 10.94 (± 1.55) 0.07
Urea nitrogen, mg/dL 61.64 (50.40–69.44) 52.23 (39.87–74.69) 0.12
Time on dialysis, months (n = 56) 14.0 (8.8–43.3) 8.0 (4.5–18.8) 0.06
No dialysis, % 26 (43.3) 13 (37.1) 0.21
<12 months 14 (23.3) 14 (40.0)
≥12 months 20 (33.3) 8 (22.9)
MMSE (n = 87) 28.5 (27.0–29.0) 27.0 (26.0–29.0) 0.15
Number of hospitalizations in previous year 1 (0–2) 1 (0–3) 0.45
Number of medications 9.0 (8.0–13.8) 12.0 (10.0–14.0) 0.03
Charlson comorbidity index score 3 (2–5) 4 (3–6) 0.02
Data are presented as: number (%), mean (± SD) or median (25–75% IQR).
Conversion factors for units: serum albumin in g/dL to g/L, ×10; serum haemoglobin in g/dL to mmol/L, ×0.6206; urea nitrogen in mg/dL to mmol/L, ×0.357.
MMSE, Mini Mental State Examination.
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instrument is only available in Dutch. Also, the high sensitivity
gave rise to a markedly high proportion of false-positive results
(43%). A CGA would help identify any underlying medical and
geriatric conditions in detail and provide valuable insight into a
patient’s ability to tolerate dialysis, thereby guiding treatment
decisions. However, they feel ‘good in themselves’ and therefore
do not consider any need to undergo a CGA or they fear a possible
diagnosis of cognitive impairment that could have consequences
on their daily living. It would be interesting to explore why a pro-
portion of ESRD patients in our study declined participation in
this straightforward frailty assessment and whether this has im-
plications for the implementation of a CGA before the initiation
of dialysis. The selection could have led to either anunderestima-
tion of the prevalence of frailty (patients feared additional diag-
noses) or an overestimation (the healthiest subjects were not
motivated for screening). Still, it is important not to overlook
any underlying clinical pathologies that can be identiﬁed using
a CGA, such as cognitive impairment, because of their possible
interference with treatment for renal failure.
Our results should be interpreted with some caution. In two
studies on community-dwelling elderly patients directly compar-
ing the GFI with the FI, it was found that these two frailty screen-
ing instruments have amoderate overlap, but that each identiﬁes
distinct groups of individuals as frail [11, 17]. Findings from one of
the two studies indicated that the GFI has a lower sensitivity for
identifying frailty in community-dwelling elderly individuals
[17] than in our dialysis population. This may be due to the
lower prevalence of comorbidities in the general population.
Two other screening instruments—the ISAR-HP and the VMS
—were originally developed to screen for the risk of functional
decline in hospitalized patients. Since functional decline and dis-
ability are strongly associated with frailty, we explored whether
both screening instruments were able to discriminate between
frail and non-frail patients. Both instruments showed moderate
sensitivity and speciﬁcity in screening for frailty, possibly due to
a lack of their applicability in an outpatient setting. The ISAR-HP
is thequickest toperform,which is usefulwhen facedwith limited
time and resource availability [9]. The VMS is less able to identify
ESRD patients who are at high risk for frailty, probably because it
does not take into account the presence of any comorbidity [8].
Although research on frailty in ESRD patients is limited,
screening and diagnostic instruments for frailty are increasingly
used in daily clinical practice. Evaluation of the discriminative
values of these instruments, as for the instruments assessed in
this study, has been hampered by the lack of a gold standard in
the scientiﬁc literature, which therefore emphasizes the need
for a consensus on the deﬁnition of frailty. The strengths of this
study included measurements of a validated construct of frailty
and screening instruments in a diverse Dutch ESRD population.
Additionally, the fact that data collection from assessments
using multiple screening instruments took place at the same
time by the same person, thus ensuring a high degree of reliable
comparabilitywithin a population. Due to the single-centre study
design including 95 participants, limitations in the statistical
power to detect small subgroup effects and in the generalizability
for the general dialysis population have to be taken into account.
Also, information on residual renal function related to mortality,
and possibly associated with frailty, was lacking.
Practical application
With a growing population of elderly dialysis and pre-dialysis pa-
tients, frailty will become an important aspect to consider in the
clinical care of ESRD patients. This study showed that different
short questionnaire–based screening instruments can be used
to screen for frailty in both young and older ESRD patients. The
instruments contribute to the identiﬁcation of those who are
frail and may beneﬁt from a CGA. Of the three screening instru-
ments assessed, the GFI demonstrated the best discriminative
value for frailty in the ESRD population, followed by the ISAR-
HP. Before implementation of any of the screening instruments
on a large scale, they should be validated ﬁrst in an independent
population. Based on the small scale of this study, it is not yet
possible to propose a ﬁrm choice for one of these instruments
or speciﬁc items in the screening for frailty. Ideally, in the future,
a choice for one speciﬁc screening instrument will be made by
international consensus, based on multiple studies. Additional-
ly, following a positive screening for frailty, the effectiveness of
a CGA on the prognostication and prevention of development
or deterioration of frailty should be investigated, e.g. by compara-
tive effectiveness research.
Table 3. Comparison of screening instruments using the Frailty Index
Frail (n = 35) Non-frail (n = 60)






value, %Frail Non-frail Frail Non-frail
Frailty Index
GFI 31 (88.6) 4 (11.4) 26 (43.3) 34 (56.7) 89 57 0.83 (0.74–0.91) 54.4 89.5
VMS 27 (77.1) 8 (22.9) 20 (33.3) 40 (66.7) 77 67 0.76 (0.65–0.86) 57.4 83.3
ISAR-HP 29 (82.9) 6 (17.1) 14 (23.3) 46 (76.7) 83 77 0.89 (0.82–0.95) 67.4 88.5
The Frailty Index [14] is used as the gold standard.
Data are presented as number (%).
AUC, area under the curve.





Dialysis (HD and PD)
(n = 56) P-value
Frail by Frailty
Index
13 (33.3) 22 (39.3) 0.55
Frail by GFI 23 (59.0) 34 (60.7) 0.87
Frail by VMS 18 (46.2) 29 (51.8) 0.59
Frail by ISAR-HP 18 (46.2) 25 (44.6) 0.88
Data are presented as number (%).
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Supplementary data
Supplementary data are available online at http://ndt.oxfordjour-
nals.org.
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